story of the week
Cabozantinib Tops Everolimus for Patients With Advanced Renal Cell Carcinoma and Bone Metastases
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Cabozantinib, a New Standard of Care for Patients With Advanced Renal Cell Carcinoma and Bone Metastases? Subgroup Analysis of the METEOR Trial
J. Clin. Oncol 2018 Jan 08;[EPub Ahead of Print], B Escudier, T Powles, RJ Motzer, T Olencki, O Arén Frontera, S Oudard, F Rolland, P Tomczak, D Castellano, LJ Appleman, H Drabkin, D Vaena, S Milwee, J Youkstetter, JC Lougheed, S Bracarda, TK ChoueiriFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.